
- /
- Supported exchanges
- / US
- / CAPR.NASDAQ
Capricor Therapeutics Inc (CAPR NASDAQ) stock market data APIs
Capricor Therapeutics Inc Financial Data Overview
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; and CAP-2003, and allogeneic cardiosphere-derived cells-exosomes, which is in preclinical trial to treat DMD. It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Capricor Therapeutics Inc data using free add-ons & libraries
Get Capricor Therapeutics Inc Fundamental Data
Capricor Therapeutics Inc Fundamental data includes:
- Net Revenue: 17 364 K
- EBITDA: -55 782 632
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: -0.318
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Capricor Therapeutics Inc News

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
NEW YORK, July 03, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such ...


General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...

B.Riley initiates Capricor Therapeutics stock with buy rating
Investing.com - B.Riley initiated coverage on Capricor Therapeutics (NASDAQ:CAPR) with a buy rating and a $21.00 price target on Thursday. According to InvestingPro data, analysts maintain a strong bu...

No Ad Comm ‘not necessarily positive’ for Capricor, says Roth Capital
Roth Capital analyst Boobalan Pachaiyappan tells investors in a research note that the FDA’s intention not to require an Ad Comm “at this time” for deramiocel for the treatment of cardiomyopathy...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.